Journal
IMMUNOLOGY LETTERS
Volume 186, Issue -, Pages 20-27Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.imlet.2017.03.018
Keywords
Short-term; Clinical efficacy; Percutaneous irreversible electroporation; NK cell; Pancreatic cancer; Clinical trial
Categories
Funding
- Science and Technology Program of Tianhe District, Guangzhou, China [201504KW008]
Ask authors/readers for more resources
This study was to determine how the short-term clinical efficacy of irreversible electroporation (IRE) combined with allogeneic natural killer (NK) cell therapy for treating metastatic pancreatic cancer. Between March and December 2016, we enrolled 40 patients who met the enrollment criteria and assigned them to two groups: simple IRE (IRE group, n = 20) and IRE plus allogeneic NK cell therapy (IRE-NK, n = 20). We evaluated immune function changes, quality of life, clinical response, and other related indicators. Combining allogeneic NK cells with IRE had a synergistic effect, not only enhancing the immune function of the patients, but also reducing the expression of carbohydrate antigen 19-9 (CA19-9) and CA242 and significantly exhibiting good short-term outcome and improving the quality of life of the patients. This is the first clinical trial to combine allogeneic NK cells with IRE for treating metastatic pancreatic cancer, and proves the safety and efficacy of the treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available